




16. (New) A pharmaceutical composition comprising (A) a benzimidazole compound represented by the following structural formula (formula 1) or an alkali metal salt thereof and (B) at least one member selected from the group consisting of sodium hydroxide, potassium hydroxide, aminoalkyl methacrylate copolymer E, arginine aspartate, hydroxypropyl cellulose and crospovidone



wherein Het<sup>1</sup> is



and Het<sup>2</sup> is



R<sup>1</sup> and R<sup>2</sup> are the same as or different from each other and are selected from hydrogen, methoxy or difluoromethoxy, R<sup>3</sup> is selected from hydrogen or sodium, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are

the same as or different from each other and are selected from hydrogen, methyl, methoxy, methoxypropoxy and trifluoroethoxy.

17. (New) The composition according to claim 16, wherein the benzimidazole compound (A) is rabeprazole, omeprazole, pantoprazole or lansoprazole.

Sub C/  
18. (New ) A pharmaceutical preparation comprising a core consisting of the composition as claimed in claim 16 and an enteric coating thereon.

19. (New ) A pharmaceutical preparation comprising a core consisting of the composition as claimed in claim 16, an intermediate coating and an enteric coating.

20. (New ) A pharmaceutical preparation comprising a core consisting of the composition as claimed in claim 16, an intermediate coating, an enteric coating and a moisture resistant coating.

21. (New) A composition comprising (A) rabeprazole or an alkali metal salt thereof and (B) is at least one member selected from the group consisting of sodium hydroxide, and potassium hydroxide.

22. (New) A composition comprising (A) rabeprazole or an alkali metal salt thereof, (B) crospovidone and at least one member selected from the group consisting of sodium hydroxide and potassium hydroxide.

23. (New) The composition according to claim 16, 21 or 22, which comprises 1 part by weight of (A) and 0.01 to 20 parts by weight of (B).

24. (New) The pharmaceutical composition of claim 16, 21 or 22 wherein components (A) and (B) are uniformly mixed with each other.

25. (New) The pharmaceutical composition of claim 16, 21 or 22 wherein (A) is mixed with a portion of (B) to form granules, then a further amount of (B) is added to the granules and mixed, then the mixture is formed into a tablet.

26. (New) The pharmaceutical composition of claim 16, 21 or 22 wherein (A) is mixed with a portion of (B) and formed into a core, then a further amount of (B) is coated as a layer onto the core.

27. (New ) A pharmaceutical preparation comprising a core consisting of the composition as claimed in claim 22 and an enteric coating.

28. (New ) A pharmaceutical preparation comprising a core consisting of the composition as claimed in claim 22, an intermediate coating and an enteric coating.

29. (New ) A pharmaceutical preparation comprising a core consisting of the composition as claimed in claim 22, an intermediate coating, an enteric coating and a moisture-resistant coating.

30. (New) The composition according to claim 22, which further comprises an antioxidant.

31. (New) The pharmaceutical preparation according to any one of claims 27, 28 and 29, wherein the core further comprises an antioxidant.

32. (New ) A pharmaceutical preparation comprising a core which comprises a drug incorporated into it, the drug being accelerated in decomposition in the presence of water and chemically unstable in gastric acid, coated with an enteric coating and further with a moisture-resistant coating.

33. (New ) A pharmaceutical preparation comprising a core which comprises a drug incorporated into it, the drug being accelerated in decomposition in the presence of water and chemically unstable in gastric acid, coated with an intermediate coating, further with an enteric coating and then with a moisture-resistant coating.

---